Keiko Esaki
Chugai Pharma (United States)(US)Toa Pharmaceutical (Japan)(JP)
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, Hemophilia Treatment and Research, Platelet Disorders and Treatments, Cell Adhesion Molecules Research, Blood Coagulation and Thrombosis Mechanisms
Most-Cited Works
- → A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model(2012)491 cited
- → Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity(2013)318 cited
- → Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens(2017)196 cited
- → Cynomolgus monkey model of interleukin‐31‐induced scratching depicts blockade of human interleukin‐31 receptor A by a humanized monoclonal antibody(2016)55 cited
- → A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state(2023)35 cited
- Generation of a humanized monoclonal antibody against human parathyroid hormone-related protein and its efficacy against humoral hypercalcemia of malignancy.(2004)
- → Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody(2017)28 cited
- → Polypeptide and Carbohydrate Structure of Recombinant Human Interleukin-6 Produced in Chinese Hamster Ovary Cells(1994)26 cited
- → Identification of tumor vascular antigens by monoclonal antibodies prepared from rat-tumor-derived endothelial cells(1998)15 cited
- → Factor VIIa inhibitors: Target hopping in the serine protease family using X-ray structure determination(2008)14 cited